<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03205228</url>
  </required_header>
  <id_info>
    <org_study_id>004/2560 (EC4)</org_study_id>
    <nct_id>NCT03205228</nct_id>
  </id_info>
  <brief_title>Treatment in Patients With Globus: Psychoeducation, Anxiolytics or Proton Pump Inhibitors</brief_title>
  <official_title>Treatment Outcomes in Patients With Globus: A Randomized Control Trial of Psychoeducation, Anxiolytics and Proton Pump Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized controlled trial study is conducted to compare treatment efficacy between
      psycho-education, anxiolytics drug and proton pump inhibitors in participants who met the
      criteria of globus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized controlled trial in patients with globus. All participants will be
      allocated into 3 groups (16 subjects/group) : Proton pump inhibitors (miracid®) , anxiolytics
      drug (Deanxit®) and psycho-education. The study duration is 4 weeks long.

      Data regarding clinical severity and quality of life of all participants will be collected at
      the beginning and at the end of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>28 days</time_frame>
    <description>Change in clinical scores assessed by Glasgow-Edinburgh throat Scale from baseline to the endo of the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in quality of life</measure>
    <time_frame>28 days</time_frame>
    <description>Changes in the scores assessed by the 36-Item Short Form Health Survey questionnaire from baseline to the end of the study.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Globus</condition>
  <arm_group>
    <arm_group_label>Flupentixol + Melitracen &amp; placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deanxit® (Flupentixol + Melitracen) 5 mg/D*4 weeks will be given</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Proton pump inhibitor &amp; placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Miracid® (Omeprazole) 20 mg/D*4 weeks will be given</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psychoeducation&amp;placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Psychoeducation by psychologists will be advised on Day 1 and Day 14 of the study time frame</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>A capsule of Omeprazole 20 mg &amp; 1 capsule of placebo will be given in individual subject, once daily for 4 weeks. Both drugs will be presented in the same appearance (white capsule).</description>
    <arm_group_label>Proton pump inhibitor &amp; placebo</arm_group_label>
    <other_name>Miracid®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>psychoeducation</intervention_name>
    <description>Psychoeducation will be given by psychologists at the Day 1 and Day 15 of the study period.One white capsule of placebo will be given once daily for 4 weeks of the study period.</description>
    <arm_group_label>Psychoeducation&amp;placebo</arm_group_label>
    <other_name>advice for symptoms management</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flupentixol +Melitracen</intervention_name>
    <description>A capsule containing of a tablet of melitracen 10 mg + flupentixol 0.5 mg &amp; a capsule of placebo will be given once daily, for 4 weeks. Both would be presented in the same appearance (white capsule)</description>
    <arm_group_label>Flupentixol + Melitracen &amp; placebo</arm_group_label>
    <other_name>Deanxit®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Symptoms based on the following criteria: Persistent or intermittent nonpainful
             sensation of a lump or foreign body in the throat with no structural lesion identified
             on physical examination, laryngoscopy, or endoscopy.

               1. Occurrence of the sensation between meals.

               2. Absence of dysphagia or odynophagia

        Exclusion Criteria:

          -  Subjects with psychological disease

          -  Significant heart disease and/or arrhythmia

          -  Proton Pump inhibitors and/or Histamine 2 Receptor Antagonist use within 2 weeks
             before randomization

          -  Mono-amine Oxidase inhibitors or Selective Serotonin Reuptake Inhibitor or Tricyclic
             antidepressant use within 2 weeks before randomization

          -  History of drug allergy that use in research

          -  Pregnancy or breast feeding

          -  Decline to participate in study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monthira Maneerattanaporn, MD., MS.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Monthira Maneerattanaporn, MD., MS.</last_name>
    <phone>6624197281</phone>
    <phone_ext>115</phone_ext>
    <email>monthira.man@mahidol.ac.th</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of gastroenterology, Department of Medicine, Siriraj hospital</name>
      <address>
        <city>Bangkok Noi</city>
        <state>Bangkok,</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monthira Maneerattanaporn, MD., MS.</last_name>
      <phone>66816979551</phone>
      <email>monthira.man@mahidol.ac.th</email>
    </contact>
    <investigator>
      <last_name>Monthira Maneerattanaporn, MD., MS.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2017</study_first_submitted>
  <study_first_submitted_qc>June 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>September 10, 2017</last_update_submitted>
  <last_update_submitted_qc>September 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
    <mesh_term>Anti-Anxiety Agents</mesh_term>
    <mesh_term>Flupenthixol</mesh_term>
    <mesh_term>Flupenthixol decanoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

